利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

516 条记录 (耗时 0.032 秒)

    Altered antibodies and their preparation
    2.
    发明申请
    Altered antibodies and their preparation 审中-公开
    改变抗体及其制备

    公开(公告)号：US20070212753A1

    公开(公告)日：2007-09-13

    申请号：US11114233

    申请日：2005-04-26

    申请人： Scott Gorman ,  Michael Clark ,  Stephen Cobbold ,  Herman Waldmann

    发明人： Scott Gorman ,  Michael Clark ,  Stephen Cobbold ,  Herman Waldmann

    IPC分类号： C12P21/06 ,  C07H21/04 ,  A61K39/395 ,  C07K16/18 ,  C12N5/06

    CPC分类号： C07K16/2812 ,  A61K38/00 ,  C07K2317/24 ,  C07K2319/00

    摘要： An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species. An antibody which is capable of binding to human CD4 antigen is also provided together with a pharmaceutical composition comprising the antibody.

    摘要翻译： 产生改变的抗体链，其中链的可变结构域的CDR衍生自第一哺乳动物物种。 编码第一种可变结构域的DNA的框架编码区被突变，使得突变的框架编码区编码来自第二种不同哺乳动物物种的框架。 抗体链的每个恒定结构域（如果存在）也衍生自第二哺乳动物物种。 能够与人CD4抗原结合的抗体也与包含抗体的药物组合物一起提供。

    Anti-atherosclerotic diaryl compounds
    8.
    发明授权
    Anti-atherosclerotic diaryl compounds 失效
    抗动脉粥样硬化二芳基化合物

    公开(公告)号：US5395853A

    公开(公告)日：1995-03-07

    申请号：US157685

    申请日：1993-11-24

    申请人： William P. Jackson ,  Clifford J. Harris ,  Richard J. Arrowsmith ,  John G. Dann ,  Kevin J. O'Connor ,  Robert F. G. Booth

    发明人： William P. Jackson ,  Clifford J. Harris ,  Richard J. Arrowsmith ,  John G. Dann ,  Kevin J. O'Connor ,  Robert F. G. Booth

    IPC分类号： C07C233/07 ,  C07C233/11 ,  C07C271/44 ,  C07C275/24 ,  C07C275/28 ,  C07C275/30 ,  C07C279/28 ,  C07C327/44 ,  A61K31/155 ,  A61K31/17 ,  C07C279/18

    CPC分类号： C07C233/07 ,  C07C233/11 ,  C07C271/44 ,  C07C275/24 ,  C07C275/28 ,  C07C275/30 ,  C07C279/28 ,  C07C327/44 ,  C07C2101/14

    摘要： The present invention is concerned with compounds of formula (I) ##STR1## wherein m is 0 or 1;W is hydrogen, a C.sub.1-16 straight, branched, or cyclic alkyl group, or a C.sub.2-16 straight, branched, or cyclic alkenyl or alkynyl group, orPh(CH.sub.2).sub.n -- where Ph is phenyl and n is an integer of from 0 to 2, the phenyl group being optionally substituted by one or more atoms or groups independently selected from halogen, hydroxy, nitro, C.sub.1-4 alkoxy and C.sub.1-4 alkyl wherein one or more of the hydrogen atoms in said alkyl group is optionally replaced by halogen, orR.sup.1 NHCO-- where R.sup.1 is hydrogen or a C.sub.1-6 alkyl group, orR.sup.2 CONH-- where R.sup.2 is hydrogen or a C.sub.1-6 alkyl group; ##STR2## Y is --(CH.sub.2).sub.q, where q is an integer of from 1 to 3, or --CH.dbd.CH-- (E or Z);Z is a C.sub.1-6 alkyl group optionally substituted by one or more independently selected polar groups; andring A is optionally substituted by one or more atoms or groups independently selected from halogen, hydroxy, nitro, C.sub.1-4 alkoxy and C.sub.1-4 alkyl wherein one or more of the hydrogen atoms in said alkyl group is optionally replaced by halogen;provided said compound of formula (I) is not N-{2-[(4-methyl-phenyl)methyl]phenyl}acetamide or .alpha.-(p-tolyl)-o-cresol carbanilate; and salts, solvates and physiologically functional derivatives thereof, processes for the preparation of these compounds, pharmaceutical formulations containing them and their use in medicine.

    摘要翻译： 本发明涉及式（I）的化合物：其中m为0或1; W是氢，C1-16直链，支链或环状烷基或C2-16直链，支链或环状烯基或炔基或Ph（CH2）n-，其中Ph是苯基，n是整数 0至2，苯基任选被一个或多个独立地选自卤素，羟基，硝基，C 1-4烷氧基和C 1-4烷基的一个或多个原子或基团取代，其中所述烷基中的一个或多个氢原子是任选的 被卤素取代，或R1NHCO-，其中R1是氢或C1-6烷基，或R2CONH-，其中R2是氢或C1-6烷基; Y是 - （CH 2）q，其中q是1至3的整数，或-CH = CH-（E或Z）; Z是任选被一个或多个独立选择的极性基团取代的C 1-6烷基; 并且环A任选被一个或多个独立地选自卤素，羟基，硝基，C 1-4烷氧基和C 1-4烷基的原子或基团取代，其中所述烷基中的一个或多个氢原子任选被卤素取代; 所述式（I）化合物不是N- {2 - [（4-甲基 - 苯基）甲基]苯基}乙酰胺或α-（对甲苯基） - 邻甲酚氨基苯甲酸酯; 及其盐，溶剂合物及其生理功能衍生物，制备这些化合物的方法，含有它们的药物制剂及其在药物中的用途。